Matinas Biopharma Holdings, Inc. (AMEX:MTNB) clinical-stage biopharmaceutical firm, is reporting third quarter earnings results on Friday 6th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.03 per share from $ 0.02 million in revenue.
For the full year, analysts predict revenues of $ 1.05 million, while looking forward to loss of $ 0.12 per share.
Stock Performance
Shares of Matinas Biopharma Holdings, Inc. traded up $ 0.00 or 0.43 percent on Thursday, reaching $ 0.85 with volume of 2.13 million shares. Matinas Biopharma Holdings, Inc. has traded high as $ 0.86 and has cracked $ 0.83 on the downward trend
According to the previous trading day, closing price of $ 0.85, representing a 71.43 % increase from the 52 week low of $ 0.49 and a 66.27 % decrease over the 52 week high of $ 2.49.
The company has a market capital of $ 168.19 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Matinas Biopharma Holdings, Inc. will be hosting a conference call at 8:30 AM eastern time on 6th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.matinasbiopharma.com
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company develops products using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals, which could encapsulate small molecules, gene therapies, vaccines, proteins, and peptides.
